ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10964	Companies
240023	Keywords
168772	Articles
129131	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

BRIEF

published on 06/24/2024 at 07:35, 2 years 2 months ago

OSE Immunotherapeutics signe un accord stratégique avec MSK pour les thérapies par cellules CAR-T

OSE Immunotherapeutics Leucémie Memorial Sloan Kettering Cancer Center CAR-T IL-7R
BRIEF

published on 06/24/2024 at 07:35, 2 years 2 months ago

OSE Immunotherapeutics signs strategic agreement with MSK for CAR-T cell therapies

OSE Immunotherapeutics Leukemia Memorial Sloan Kettering Cancer Center CAR-T IL-7R
PRESS RELEASE

published on 06/24/2024 at 07:30, 2 years 2 months ago

OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T
OSE Immunotherapeutics annonce un accord avec le Memorial Sloan Kettering Cancer Center pour les thérapies CAR-T. L'accord porte sur des brevets dans le traitement des cancers exprimant l'IL-7R

Brevets OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center IL-7R Thérapies CAR-T
PRESS RELEASE

published on 06/24/2024 at 07:30, 2 years 2 months ago

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
OSE Immunotherapeutics partners with Memorial Sloan Kettering Cancer Center for CAR T-cell therapy agreement. MSK to lead development and share revenues with OSE

Agreement CAR T-cell Therapy OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center Revenue Sharing
BRIEF

published on 06/20/2024 at 07:35, 2 years 2 months ago

OSE Immunotherapeutics présente des données prometteuses sur la plateforme ARNm au congrès FOCIS

Maladies Auto-immunes OSE Immunotherapeutics ARNm Thérapeutique FOCIS 2024 IL-35
BRIEF

published on 06/20/2024 at 07:35, 2 years 2 months ago

OSE Immunotherapeutics presents promising data on the mRNA platform at the FOCIS congress

Autoimmune Diseases OSE Immunotherapeutics FOCIS 2024 IL-35 Therapeutic MRNA
PRESS RELEASE

published on 06/20/2024 at 07:30, 2 years 2 months ago

OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)
OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique au congrès annuel FOCIS à San Francisco. L'IL-35 joue un rôle clé dans le contrôle des maladies auto-immunes et inflammatoires

Maladies Auto-immunes OSE Immunotherapeutics ARNm Thérapeutique IL-35 FOCIS
BRIEF

published on 06/05/2024 at 07:35, 2 years 3 months ago

OSE Immunotherapeutics et le CHU de Nantes Présentent des Résultats Positifs en Transplantation Rénale

Immunothérapie Essai Clinique OSE Immunotherapeutics Transplantation Rénale FR104/VEL-101
BRIEF

published on 06/05/2024 at 07:35, 2 years 3 months ago

OSE Immunotherapeutics and Nantes University Hospital Present Positive Results in Renal Transplantation

Immunotherapy Clinical Test OSE Immunotherapeutics FR104/VEL-101 Kidney Transplantation
PRESS RELEASE

published on 06/05/2024 at 07:30, 2 years 3 months ago

OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale
OSE Immunotherapeutics et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l'essai clinique de Phase 1/2 évaluant l'immunothérapie FR104/VEL-101 en transplantation rénale au congrès 'American Transplant Congress' 2024

Essai Clinique OSE Immunotherapeutics Transplantation Rénale FR104/VEL-101 Centre Hospitalier Universitaire De Nantes

Accesswire

Published on 09/11/2026 at 04:00, 7 hours 20 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 12 hours 55 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 17 hours 34 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 20 hours ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 20 hours 20 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 10:15, 1 hour 5 minutes ago

TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 09:20, 2 hours ago

Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 2 hours 15 minutes ago

ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 2 hours 20 minutes ago

Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 09:00, 2 hours 20 minutes ago

Picton Property Income Limited - Removal

Les Echos

Published on 09/11/2026 at 07:00, 4 hours 20 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 4 hours 20 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 4 hours 20 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 4 hours 20 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 15 hours 50 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE